BR0015227A - Derivados de benzopiranil guanidina, processo para a sua preparação e composições farmacêuticas contendo os mesmos - Google Patents

Derivados de benzopiranil guanidina, processo para a sua preparação e composições farmacêuticas contendo os mesmos

Info

Publication number
BR0015227A
BR0015227A BR0015227-7A BR0015227A BR0015227A BR 0015227 A BR0015227 A BR 0015227A BR 0015227 A BR0015227 A BR 0015227A BR 0015227 A BR0015227 A BR 0015227A
Authority
BR
Brazil
Prior art keywords
guanidine derivatives
preparation
benzopyranil
pharmaceutical compositions
compositions containing
Prior art date
Application number
BR0015227-7A
Other languages
English (en)
Other versions
BR0015227B1 (pt
Inventor
Sung-Eun Yoo
Kyu Yang Yi
Sun Kyung Lee
Nak-Jung Kim
Jee Hee Suh
Young Sook Park
Sun Kyung Hwang
Hwa Sup Shin
Byung Ho Lee
Ho Won Seo
Hong Lim
Sun-Ok-Kim
In Sun Cho
Mi Ae Namkoong
Dong Soo Jang
Original Assignee
Dongbu Hannong Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2000-0060467A external-priority patent/KR100429609B1/ko
Application filed by Dongbu Hannong Chemical Co Ltd filed Critical Dongbu Hannong Chemical Co Ltd
Publication of BR0015227A publication Critical patent/BR0015227A/pt
Publication of BR0015227B1 publication Critical patent/BR0015227B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE BENZOPIRANIL GUANIDINA, PROCESSO PARA A SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS". A presente invenção refere-se a derivados de benzopiranil guanidina da fórmula (1), onde R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~ n e * são, cada um, definidos no pedido, processo para a preparação deles e uso farmacêutico dos derivados de benzopiranil guanidina. Os derivados de benzopiranil guanidina da presente invenção podem ser usados para proteção do coração, célula neuronal ou dano cerebral, órgãos de conservação, e também os derivados de benzopiranil guanidina são farmacologicamente úteis para inibição de geração de NO, e para supressão de peroxidação de lipídeo, angiogênese e restenose.
BRPI0015227-7A 1999-10-21 2000-10-20 derivados de benzopiranil guanidina, processo para a sua preparaÇço e composiÇÕes farmacÊuticas contendo os mesmos. BR0015227B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19990045871 1999-10-21
KR10-2000-0060467A KR100429609B1 (ko) 1999-10-21 2000-10-13 벤조피라닐 구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
PCT/KR2000/001189 WO2001029023A1 (en) 1999-10-21 2000-10-20 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
BR0015227A true BR0015227A (pt) 2002-07-16
BR0015227B1 BR0015227B1 (pt) 2011-12-27

Family

ID=36763698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015227-7A BR0015227B1 (pt) 1999-10-21 2000-10-20 derivados de benzopiranil guanidina, processo para a sua preparaÇço e composiÇÕes farmacÊuticas contendo os mesmos.

Country Status (11)

Country Link
EP (1) EP1228058B1 (pt)
JP (1) JP3999515B2 (pt)
CN (1) CN1229371C (pt)
AU (1) AU1175001A (pt)
BR (1) BR0015227B1 (pt)
CA (1) CA2387727C (pt)
DE (1) DE60007168T2 (pt)
ES (1) ES2210009T3 (pt)
HK (1) HK1051538A1 (pt)
MX (1) MXPA02003898A (pt)
WO (1) WO2001029023A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100492252B1 (ko) * 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
KR100512486B1 (ko) * 2003-05-28 2005-09-06 동부한농화학 주식회사 싸이옥소벤즈옥사졸 유도체로 치환된 벤조피란 유도체또는 약학적으로 허용되는 염, 이의 제조방법 및 이를포함하는 약학적 조성물
KR100545780B1 (ko) * 2003-05-28 2006-01-24 동부한농화학 주식회사 벤즈이미다졸 유도체로 치환된 벤조피란 유도체 또는약학적으로 허용되는 그의 염, 이의 제조 방법 및 이를포함하는 약학적 조성물
EP2487171A1 (en) * 2011-02-08 2012-08-15 Université de Liège Dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy
CA2877326A1 (en) * 2012-06-28 2014-01-03 Abbvie Inc. Cyanoguanidines and their use as antiviral agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02172984A (ja) * 1988-12-23 1990-07-04 Yamanouchi Pharmaceut Co Ltd クロマン誘導体
US5140031A (en) * 1989-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Pyranyl cyanoguanidine derivatives
CA2015296C (en) * 1989-05-31 2001-08-07 Karnail Atwal Pyranyl cyanoguanidine derivatives
JPH05186458A (ja) * 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体

Also Published As

Publication number Publication date
DE60007168D1 (de) 2004-01-22
DE60007168T2 (de) 2004-12-30
CA2387727C (en) 2008-10-14
CN1382134A (zh) 2002-11-27
EP1228058A1 (en) 2002-08-07
EP1228058B1 (en) 2003-12-10
CN1229371C (zh) 2005-11-30
JP3999515B2 (ja) 2007-10-31
ES2210009T3 (es) 2004-07-01
MXPA02003898A (es) 2003-07-14
BR0015227B1 (pt) 2011-12-27
WO2001029023A1 (en) 2001-04-26
HK1051538A1 (en) 2003-08-08
EP1228058A4 (en) 2003-02-12
AU1175001A (en) 2001-04-30
JP2003512367A (ja) 2003-04-02
CA2387727A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
CA2216796A1 (en) Quinazoline derivatives
CA2302396A1 (en) Allosteric adenosine receptor modulators
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
TR200000482T2 (tr) N-Aroilfenilalanin türevleri.
BR0213843A (pt) Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
EP1362846A4 (en) AMINOETHANOLDERIVATE
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
ATE281446T1 (de) Benzofuranonderivate enthaltende formulierung zum schutz vor oxidativem stress
TNSN87012A1 (fr) Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
BR0015227A (pt) Derivados de benzopiranil guanidina, processo para a sua preparação e composições farmacêuticas contendo os mesmos
CA2305933A1 (fr) Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
CA2382322A1 (en) Aminocarbonyl-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions
BR9813217A (pt) Tetraciclos, processo para a produção dos mesmos e preparações farmacêuticas contendo estes compostos
BR0309014A (pt) ácido(2-((2-alcóxi)-fenil)-ciclopent-1-enil)carbo e heterocìclico aromático e derivados
BR0309130A (pt) Derivados de acil-3-carboxifenil-uréia, processo para a sua preparação e sua aplicação
BR0003352A (pt) Fenilpirazóis, uso dos mesmos, processo para prepará-los, composições herbicidas, e, processo para controlar ervas daninhas em áreas cultivadas
BR9805437A (pt) Derivados de benzocicloalquenos heterocìclicos, processo para fabricação de derivados de benzocicloalquenos heterocìclicos e uso de derivados de benzocicloalquenos heterocìclicos.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
HUP0303319A2 (hu) 9-Dezoxo-9-dihidro-9a-aza-9a-homoeritromicin A és 5-O-dezozaminil-9-dezoxo-9-dihidro-9a-aza-9a-homoeritronolid A 9a-N-[N'-(fenil-szulfonil)karbamoil]-származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69801811T2 (de) Alkykendiamin di- oder tri-essigsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in kosmetischen zusammensetzungen
BRPI0012329B8 (pt) derivados de benzofurano, processo para sua preparação e uso dos mesmos.
EP0761214A3 (en) N,N-disubstituted anilines or alkylamines as singlet oxygen quenchers, topical compositions comprising them
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları

Legal Events

Date Code Title Description
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 12A, 13A, 14A E 15A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.